ArticleApplied and environmental microbiology2007
Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae.
Article in Applied and environmental microbiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands.BMC gastroenterology · 2018Guideline
- Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.World journal of gastroenterology · 2010Pooled it
- Effects of supplementing with Saccharomyces boulardii on vonoprazan-amoxicillin dual therapy for naive Helicobacter pylori infection: a randomized controlled trial.BMC gastroenterology · 2026Trial
- Trial
- Oral Mycobiome Alterations in Children with Phenylketonuria: Associations with Dietary Intake and Metabolic Context-A Pilot Study.Nutrients · 2026Article
- Article
- Molecular Genetics and Probiotic Mechanisms of Saccharomyces cerevisiae var. boulardii.Probiotics and antimicrobial proteins · 2026Review
- Brewing a Cure: Engineering Yeast to Reduce Inflammation-Driven Tumors.Digestive diseases and sciences · 2025Article
- Application ofIranian journal of microbiology · 2025Review
- Genomic and phenotypic comparison ofbioRxiv : the preprint server for biology · 2025Article
- Systematic Engineering for Efficient Uric Acid-Degrading Activity in Probiotic YeastACS synthetic biology · 2025Article
- Does tablet shape and height influence survival of fluidized bed-granulated living microorganisms during compaction?International journal of pharmaceutics: X · 2025Article
- Metabolic Influence ofJournal of fungi (Basel, Switzerland) · 2025Article
- A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden.Cell chemical biology · 2025Article
- High-Resolution Melting Analysis Potential forBiotech (Basel (Switzerland)) · 2024Article
- Novel Insights in the Application of Probiotic YeastFoods (Basel, Switzerland) · 2024Review
- A Probiotic Amylase Blend Positively Impacts Gut Microbiota Modulation in a Randomized, Placebo-Controlled, Double-Blind Study.Life (Basel, Switzerland) · 2024Article
- Enhancing probiotic impact: engineeringApplied and environmental microbiology · 2024Article
- The preventive effects ofHeliyon · 2024Article
- Anti-Cariogenic Effects ofPharmaceutics · 2024Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Saccharomyces boulardii, a yeast that was isolated from fruit in Indochina, has been used as a remedy for diarrhea since 1950 and is now a commercially available treatment throughout Europe, Africa, and South America. Though initially classified as a separate species of Saccharomyces, recent publications have shown that the genome of S. boulardii is so similar to Saccharomyces cerevisiae that the two should be classified as conspecific. This raises the question of the distinguishing molecular and phenotypic characteristics present in S. boulardii that make it perform more effectively as a probiotic organism compared to other strains of S. cerevisiae. This investigation reports some of these distinguishing characteristics including enhanced ability for pseudohyphal switching upon nitrogen limitation and increased resistance to acidic pH. However, these differences did not correlate with increased adherence to epithelial cells or transit through mouse gut. Pertinent characteristics of the S. boulardii genome such as trisomy of chromosome IX, altered copy number of a number of individual genes, and sporulation deficiency have been revealed by comparative genome hybridization using oligonucleotide-based microarrays coupled with a rigorous statistical analysis. The contributions of the different genomic and phenotypic features of S. boulardii to its probiotic nature are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.